Black fungus: Center allocates 29,250 additional vials of Amphotericin-B to States and UTs

Earlier, additional 19,420 vials of Amphotericin- B were allocated on 24th May and 23,680 vials of the drug were supplied across the country on 21st May, the Ministry of Chemicals and Fertilizers info

Published: 26th May 2021 03:29 PM  |   Last Updated: 26th May 2021 03:29 PM   |  A+A-

Patients infected with black fungus are treated at the Mucormycosis ward of a government hospital in Ahmedabad. (Photo | AP)

By ANI

NEW DELHI: The Union Minister for Chemicals and Fertilizers Sadananda Gowda informed on Wednesday that additional 29,250 vials of Amphotericin-B, used in the treatment of Mucormycosis, were allocated to States and Union Territories, based on their number of patients under treatment.

The minister tweeted, "Additional 29,250 vials of #Amphotericin- B drug, used in treatment of #Mucormycosis, have been allocated to all the States/UTs today. The allocation has been made based on the number of patients under treatment which is 11,717 across the country".

Earlier, additional 19,420 vials of Amphotericin- B were allocated on 24th May and 23,680 vials of the drug were supplied across the country on 21st May, the Ministry of Chemicals and Fertilizers informed. 


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.